Diatech Pharmacogenetics is pleased to announce the release of its CE-IVD RealQuant® Lung Fusion Genes kit for the detection and quantification through NanoString® technology of the fusion transcripts of the genes ALK, ROS1 and RET in non-small cell lung cancer (NSCLS).
Lung cancer is the first tumor in terms of incidence and mortality among men and it represents the third one in incidence, the second one in mortality, among women.
The NSCLC represents the 85% of all lung cancer cases. In a small fraction of NSCLC cases ranging from 1% to 7% it has been observed some chromosomal translocations which involve ALK, ROS1 or RET genes conferring sensitivity to the therapy with specific tyrosine-kinase inhibitors (TKIs). Crizotinib (Xalkori) is indicated for the treatment of patients with NSCLC in advanced stage and positive for fusion of ALK or ROS1 genes on the front line or after chemotherapy treatment. Ceritinib (Zykadia), initially approved only for treatment of advanced stage NSCLC and positive ALK patients, also resistant and intolerant to crizotinib, it has recently been authorized by FDA to be used also on the front line.
Alectinib (Alecensa) has been approved by EMA two months ago for the treatment of patients with advanced stage NSCLC and ALK translocation, whose disease progresses during or shortly after the therapy with Crizotinib. Other TKIs, such as Vandetanib and Cabozantinib, are in an advanced clinical trial phase for the treatment of NSCLS positive for RET rearrangements.
Enter your information below to download the brochure

Category
Gene Expression